PROTAC-3 was developed based on the ATP-competitive FAK inhibitor Defactinib (Table 1) fusing to the E3 ubiquitin ligase VHL, and has been shown to be more effective in inhibiting the activation of FAK and FAK-dependent cell migration and invasion in breast cancer cells in vitro [58]. The gene discussed is PTK2; the disease is breast cancer.